Advanced

Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17 beta-estradiol and norethisterone acetate

Samsioe, Göran LU ; Li, Cairu LU ; Borgfeldt, Christer LU ; Wilawan, K; Åberg, Anders E LU and Larsen, S (2002) In Menopause 9(5). p.335-342
Abstract
Objective: To evaluate the modification of lipid and lipoprotein by use of low doses of continuous-combined formulations of 17beta-estradiol (E-2) and norethisterone acetate (NETA) in healthy postmenopausal women. Design: The study was designed as a double-blind, randomized, placebo-controlled trial. A total of 120 healthy postmenopausal women were randomized to one of three treatment arms: (1) placebo group (n = 40); (2) E-2/NETA 0.25-mg group-subjects receiving oral continuous-combined E-2 1 mg and NETA 0.25 mg (n = 40); (3) E2/NETA 0.5-mg group-women who were treated with E-2 1 mg and NETA 0.5 mg (n = 40). The duration of study was 12 months. Plasma levels of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein... (More)
Objective: To evaluate the modification of lipid and lipoprotein by use of low doses of continuous-combined formulations of 17beta-estradiol (E-2) and norethisterone acetate (NETA) in healthy postmenopausal women. Design: The study was designed as a double-blind, randomized, placebo-controlled trial. A total of 120 healthy postmenopausal women were randomized to one of three treatment arms: (1) placebo group (n = 40); (2) E-2/NETA 0.25-mg group-subjects receiving oral continuous-combined E-2 1 mg and NETA 0.25 mg (n = 40); (3) E2/NETA 0.5-mg group-women who were treated with E-2 1 mg and NETA 0.5 mg (n = 40). The duration of study was 12 months. Plasma levels of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very low-density lipoprotein (VLDL) cholesterol, triglycerides, lipoprotein(a), apolipoprotein A and apolipoprotein B were determined on four occasions (i.e., baseline, 3-, 6-, and 12-month visits). Results: There were no differences in the baseline characteristics among the three groups. A total of 102 women completed the study, resulting in a compliance rate of 85%. There was a significant reduction of total cholesterol, LDL cholesterol, and lipoprotein(a) in both combined groups when compared with placebo. The level of apolipoprotein B declined significantly only in the E-2/NETA 0.25-mg group. Decrements were observed within 3 months of treatment and maintained thereafter. No significant changes were found in triglycerides, VLDL cholesterol, HDL cholesterol, apolipoprotein A, and LDL/HDL ratio. Between the two active combined groups, no statistically significant differences were noted. Conclusion: Favorable changes in lipids and lipoproteins were associated with the low dose of E-2/NETA combinations. These effects may contribute to the reduction or prevention of atherogenesis in postmenopausal women. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
replacement therapy, hormone, lipoprotein, lipid, estradiol, norethisterone acetate
in
Menopause
volume
9
issue
5
pages
335 - 342
publisher
Lippincott-Raven Publishers
external identifiers
  • wos:000177857200006
ISSN
1530-0374
DOI
10.1097/01.GME.0000019564.35939.F8
language
English
LU publication?
yes
id
d2947f44-dfb5-4a12-914b-fc2ae6c9f261 (old id 329082)
date added to LUP
2007-11-09 09:42:18
date last changed
2016-04-15 19:36:38
@article{d2947f44-dfb5-4a12-914b-fc2ae6c9f261,
  abstract     = {Objective: To evaluate the modification of lipid and lipoprotein by use of low doses of continuous-combined formulations of 17beta-estradiol (E-2) and norethisterone acetate (NETA) in healthy postmenopausal women. Design: The study was designed as a double-blind, randomized, placebo-controlled trial. A total of 120 healthy postmenopausal women were randomized to one of three treatment arms: (1) placebo group (n = 40); (2) E-2/NETA 0.25-mg group-subjects receiving oral continuous-combined E-2 1 mg and NETA 0.25 mg (n = 40); (3) E2/NETA 0.5-mg group-women who were treated with E-2 1 mg and NETA 0.5 mg (n = 40). The duration of study was 12 months. Plasma levels of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very low-density lipoprotein (VLDL) cholesterol, triglycerides, lipoprotein(a), apolipoprotein A and apolipoprotein B were determined on four occasions (i.e., baseline, 3-, 6-, and 12-month visits). Results: There were no differences in the baseline characteristics among the three groups. A total of 102 women completed the study, resulting in a compliance rate of 85%. There was a significant reduction of total cholesterol, LDL cholesterol, and lipoprotein(a) in both combined groups when compared with placebo. The level of apolipoprotein B declined significantly only in the E-2/NETA 0.25-mg group. Decrements were observed within 3 months of treatment and maintained thereafter. No significant changes were found in triglycerides, VLDL cholesterol, HDL cholesterol, apolipoprotein A, and LDL/HDL ratio. Between the two active combined groups, no statistically significant differences were noted. Conclusion: Favorable changes in lipids and lipoproteins were associated with the low dose of E-2/NETA combinations. These effects may contribute to the reduction or prevention of atherogenesis in postmenopausal women.},
  author       = {Samsioe, Göran and Li, Cairu and Borgfeldt, Christer and Wilawan, K and Åberg, Anders E and Larsen, S},
  issn         = {1530-0374},
  keyword      = {replacement therapy,hormone,lipoprotein,lipid,estradiol,norethisterone acetate},
  language     = {eng},
  number       = {5},
  pages        = {335--342},
  publisher    = {Lippincott-Raven Publishers},
  series       = {Menopause},
  title        = {Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17 beta-estradiol and norethisterone acetate},
  url          = {http://dx.doi.org/10.1097/01.GME.0000019564.35939.F8},
  volume       = {9},
  year         = {2002},
}